Key Dates

Related Announcements

• September 13, 2023 - NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional). See NOFO PAR-23-275.
• July 12, 2023- PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). See NOFO PA-23-230.
• July 12, 2023- PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required). See NOFO PA-23-231.
• July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed). See NOFO PA-23-232.
• March 6, 2023 - Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required). See NOFO PAS-23-086.
• September 12, 2022 - Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional). See NOFO PAR-22-129.
• August 25, 2022- Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional). See NOFO PAR-23-024.
• November 30, 2021- High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional). See NOFO PAR-22-069.
• August 20, 2021- Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional). See NOFO PAR-21-313.
• August 17, 2021 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed). See NOFO PAR-21-271.
• December 23, 2020 - NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required). See NOFO PAR-21-102.
• December 23, 2020 - NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed). See NOFO PAR-21-103.
• December 23, 2020 - NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional). See NOFO PAR-21-101.
• May 12, 2020 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed). See NOFO PA-20-203.
• May 12, 2020 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed). See NOFO PA-20-205.
• May 12, 2020 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required). See NOFO PA-20-206.
• May 7, 2020 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required). See NOFO PA-20-197.
• May 7, 2020 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed). See NOFO PA-20-199.
• May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required). See NOFO PA-20-176.
• May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed). See NOFO PA-20-190.
• May 5, 2020 - Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183.
• May 5, 2020 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required). See NOFO PA-20-184.
• May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185.
• May 5, 2020 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required). See NOFO PA-20-187.
• May 5, 2020 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed). See NOFO PA-20-188.

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

Background

Creating pathways to health for all Americans to live the longest and healthiest lives possible is essential to foster vibrant, healthy communities and the country’s overall productivity. Many of the diseases and disorders that disproportionately affect the health of underserved populations in the United States are high priority research areas for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). African Americans, Hispanic Americans, American Indians, Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, people with lower socioeconomic status, sexual and gender minority groups, people with disabilities, and rural populations experience much higher risks of and poorer health status than the majority population.

The NIDDK’s Strategic Plan highlights a cross-cutting theme of achieving health equity by eliminating health disparities among racial and ethnic minority populations and others who are underserved. Furthermore, the Pathways to Health for All report from the NIDDK Advisory Council Working Group on Health Disparities and Health Equity acknowledges the need for and encourages NIDDK to pursue research on broader social, environmental, structural, and systemic drivers of population health and health disparities to promote greater health equity.

NIDDK invites research to improve understanding of the causes of disparities in health and disability in the United States with the goal of achieving health equity by improving health and reducing or eliminating health disparities within the mission of the NIDDK: https://www.niddk.nih.gov/about-niddk/research-areas. Specifically, NIDDK welcomes applications that explore the overarching recommendations, each with corresponding opportunities, for high-impact research and actionable strategies elaborated in the Pathways to Health for All report, including:

1. Strengthening community engagement through partnership, power-sharing, and capacity building to improve research
2. Advancing research on the mechanisms by which biological, behavioral, environmental, and structural factors interact to affect health, disease, and resilience
3. Advancing research on interventions and studies to address racism, health-related social needs, and social determinants of health
4. Promoting new methods, measures, tools, and technologies to accelerate achievement of health equity research goals

Objectives and Scope

This NOSI invites applications for research to understand and mitigate health disparities in the prevention, development, diagnosis, treatment and progression of diseases and conditions of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is recognized that health disparities are driven by factors operating at multiple levels (i.e., individual, interpersonal, community, societal) and domains (e.g., biological, behavioral, sociocultural, physical/built environment, etc.) and interacting in complex ways. (Refer to the NIMHD Minority Health and Health Disparities Research Framework.)

Research approaches may include observational, interventional, and dissemination and implementation research studies in representative populations. Basic science studies including animal models are responsive if they clearly justify how the proposed research will serve to advance health equity or address a known disparity.

NIDDK is interested in study designs that include integrative approaches to address multilevel and multi-domain factors (and their interactions) that cause or contribute to disparities across the life course, such as exposure to structural, institutional, interpersonal, or internalized racism or discrimination; differences in social determinants of health effects; structural conditions; and other upstream factors and root causes. NIDDK is also interested in understanding how such factors operate across multiple intersecting socially marginalized identities. Community-engaged and community-led approaches that emphasize the priorities and needs of individuals and populations disparately affected by NIDDK diseases and conditions are strongly encouraged.

NIDDK also encourages applications that demonstrate consideration of the Tips for Pursuing Competent Health Equity Research (see Appendix G of Pathways to Health for All). This includes applications with interdisciplinary research teams comprised of individuals with a breadth of lived experiences and biomedical scientific expertise deemed necessary to positively inform the study design, research conduct, and applicability of research findings for the populations of interest.

Applications will only be considered responsive to this NOSI when proposing health disparities or minority health research that occurs in the United States and its territories. Applications must also propose research relevant to designated populations that experience health disparities (US racial/ethnic minority, low socioeconomic status, sexual and gender minorities, rural, and disability populations), or provide justification for those populations not officially designated (see page 10 of Pathways to Health for All).

Applicants should refer to the target NOFO to determine if a Clinical Trial may be proposed under this NOSI.

Investigators who would like to submit a high risk multi-center clinical study or trial should refer to NOT-DK-20-051: NIDDK Investigator-Initiated Multi-Center Clinical Studies Revised Guidance

Application and Submission Information

This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 8, 2027.

Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice.

All instructions in the SF424 (R&R) Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

• For funding consideration, applicants must include NOT-DK-24-007 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.